Fig 1.
A and B. Efficiency frontier: plot of incremental (A) life years (LYs) and (B) quality-adjusted life years (QALYs) and costs of non-curative palliative treatments: i) transarterial chemoembolization (TACE) alone or TACE+sorafenib; ii) non-sorafenib chemotherapy alone; and iii) sorafenib alone relative to lowest cost scenario (no treatment or best supportive care [BSC]). The dotted diagonal line represents the ceiling ratio. If an intervention lies above the line, it will not be acceptable on cost-effectiveness grounds.